Item 8. Financial Statements and Supplementary Data
ITEM 8. FINANCIAL STATEMENTS
AND SUPPLEMENTARY DATA.
Index to Financial Statements
Page
Report of Independent Registered Public Accounting Firm (PCAOB No. 577 )
F-1
Balance Sheets at June 30, 2025 and 2024
F-3
Statements of Operations for the Years Ended June 30, 2025 and 2024
F-4
Statements of Stockholders’ Equity for the Years Ended June 30, 2025 and 2024
F-5
Statements of Cash Flows for the Years Ended June 30, 2025 and 2024
F-6
Notes to Financial Statements
F-7
22
Report of Independent Registered Public Accounting
Firm
To the Board of Directors and
Stockholders of Precision Optics Corporation, Inc.
Opinion on the Financial Statements
We have audited the accompanying balance sheets
of Precision Optics Corporation, Inc. (the “Company”) as of June 30, 2025 and 2024, and the related statements of operations,
stockholders’ equity, and cash flows for each of the years in the two year period ended June 30, 2025, and the related notes (collectively
referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects,
the financial position of the Company as of June 30, 2025 and 2024, and the results of its operations and its cash flows for each of the
years in the two year period ended June 30, 2025, in conformity with accounting principles generally accepted in the United States of
America.
Basis for Opinion
These financial statements are the responsibility
of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our
audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (PCAOB) and are required to be independent
with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities
and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged
to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding
of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s
internal control over financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matters
The critical audit matters communicated below
is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to
the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our
especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion
on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions
on the critical audit matters or on the accounts or disclosures to which they relate.
Revenue Recognition — Refer to Note
A to the Financial Statements
Critical Audit Matter Description
The Company recognizes revenue upon transfer of
control of promised products to customers in an amount that reflects the consideration the Company expects to receive in exchange for
those products. The Company may enter into certain customer contracts that contain unique, customer-specific terms and conditions, variable
consideration, as well as multiple performance obligations. For such contracts, significant interpretation may be required to determine
the appropriate accounting, including the identification of performance obligations, the allocation of the transaction price to performance
obligations in the arrangement, the timing of the transfer of control of promised goods for each of those performance obligations, estimates
of variable consideration and agent versus principal consideration.
Our assessment of managements’ evaluation
of the above referenced matters related to proper revenue recognition is significant to our audit because of the nature and extent of
audit effort required to address the matter, the amounts are material to the financial statements, the assessment process involves significant
auditor judgment, and the application of U.S. generally accepted accounting principles in this area is complex.
F- 1
How the Critical Audit Matter Was Addressed in the Audit
Our principal audit procedures related to the
Company’s revenue recognition for customer contracts included the following:
·
We evaluated the appropriateness of management’s revenue recognition policies.
·
We tested the mathematical accuracy of management’s calculations of revenue and the associated timing of revenue recognized in the financial statements.
·
We selected a sample of revenue transactions and performed the following procedures:
o
Obtained and read source documents for each selection, including master agreements, purchase orders and other documents that evidenced the customer arrangement.
o
Tested management’s identification and treatment of the key contract terms, including performance obligations and variable consideration.
o
Assessed the terms in the customer agreement and evaluated the appropriateness of management’s application of the Company’s accounting policies, along with their use of estimates, in the determination of revenue recognition conclusions.
/s/ Stowe & Degon LLC
Westborough, Massachusetts
September 29, 2025
We have served as the Company’s auditor
since 2008
F- 2
PRECISION OPTICS CORPORATION, INC.
Balance Sheets at June 30, 2025 and 2024
2025
2024
ASSETS
Current Assets:
Cash and cash equivalents
$ 1,773,735
$ 405,278
Accounts receivable, net of allowance for credit losses of $ 80,192 at June 30, 2025 and $ 118,872 at June 30, 2024
4,336,730
3,545,491
Inventories, net
3,562,112
2,868,100
Prepaid expenses
385,390
299,364
Total current assets
10,057,967
7,118,233
Fixed Assets:
Machinery and equipment
3,385,958
3,341,194
Leasehold improvements
871,356
810,914
Furniture and fixtures
538,428
416,425
Total fixed assets
4,795,742
4,568,533
Less—Accumulated depreciation and amortization
4,261,950
4,074,960
Net fixed assets
533,792
493,573
Operating lease right-of-use asset
141,825
189,999
Patents, net
232,493
286,559
Goodwill
8,824,210
8,824,210
Total other assets
9,198,528
9,300,768
TOTAL ASSETS
$ 19,790,287
$ 16,912,574
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Revolving line of credit
$ –
$ 1,000,000
Current portion of capital lease obligation
27,368
41,113
Current maturities of long-term debt
577,898
276,928
Accounts payable
2,909,100
1,397,313
Customer advances
1,821,929
1,172,350
Accrued compensation and other
764,004
840,662
Operating lease liability
50,995
178,450
Total current liabilities
6,151,294
4,906,816
Capital lease obligation, net of current portion
–
27,369
Long-term debt, net of current maturities
1,289,205
1,899,052
Operating lease liability, net of current portion
90,954
11,549
Total liabilities
7,531,453
6,844,786
Stockholders’ Equity:
Common stock, $ 0.01 par value: 50,000,000 shares authorized; issued and outstanding – 7,714,701 shares at June 30, 2025 and 6,073,939 shares at June 30, 2024
77,147
60,739
Additional paid-in capital
69,152,317
61,197,433
Accumulated deficit
( 56,970,630 )
( 51,190,384 )
Total stockholders’ equity
12,258,834
10,067,788
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY
$ 19,790,287
$ 16,912,574
The accompanying notes are an integral part
of these financial statements.
F- 3
PRECISION OPTICS CORPORATION, INC.
Statements of Operations
for the Years Ended June 30, 2025 and 2024
2025
2024
Revenues
$ 19,091,269
$ 19,104,350
Cost of goods sold
15,686,836
13,306,573
Gross profit
3,404,433
5,797,777
Research and development expenses, net
1,157,963
981,781
Selling, general and administrative expenses
7,797,761
7,540,329
Total operating expenses
8,955,724
8,522,110
Operating loss
( 5,551,291 )
( 2,724,333 )
Other expense
Interest expense
( 227,019 )
( 225,108 )
Loss before provision for income taxes
( 5,778,310 )
( 2,949,441 )
Provision for income taxes
1,936
1,936
Net loss
$ ( 5,780,246 )
$ ( 2,951,377 )
Loss per share:
Basic and fully diluted
$ ( 0.85 )
$ ( 0.49 )
Weighted average common shares outstanding:
Basic and fully diluted
6,790,466
6,068,329
The accompanying notes are an integral part
of these financial statements.
F- 4
PRECISION OPTICS CORPORATION, INC.
Statements of Stockholders’ Equity
for the Years Ended June 30, 2025 and 2024
Number of
Shares
Common
Stock
Additional
Paid-in
Capital
Accumulated
Deficit
Total
Stockholders’
Equity
Balance, June 30, 2023
6,066,518
$ 60,665
$ 60,224,934
$ ( 48,239,007 )
$ 12,046,592
Proceeds from exercise of stock option
4,333
43
12,746
–
12,789
Exercise of stock options net of 2,916 shares withheld
3,088
31
( 31 )
–
–
Stock-based compensation
–
–
959,784
–
959,784
Net loss
–
–
–
( 2,951,377 )
( 2,951,377 )
Balance, June 30, 2024
6,073,939
$ 60,739
$ 61,197,433
$ ( 51,190,384 )
$ 10,067,788
Issuance of common stock in a registered direct offering
1,538,368
15,384
6,254,752
–
6,270,136
Proceeds from exercise of stock option
71,979
721
88,329
–
89,050
Issuance of common stock for consulting services and employees
30,415
303
151,395
–
151,698
Stock-based compensation
–
–
1,460,408
–
1,460,408
Net loss
–
–
–
( 5,780,246 )
( 5,780,246 )
Balance, June 30, 2025
7,714,701
$ 77,147
$ 69,152,317
$ ( 56,970,630 )
$ 12,258,834
The accompanying notes are an integral part
of these financial statements.
F- 5
PRECISION OPTICS CORPORATION, INC.
Statements of Cash Flows
For the Years Ended June 30, 2025 and 2024
2025
2024
Cash Flows from Operating Activities:
Net loss
$ ( 5,780,246 )
$ ( 2,951,377 )
Adjustments to reconcile net loss to net cash (used in) provided by operating activities-
Depreciation and amortization
212,439
212,382
Stock-based compensation expense
1,460,408
959,784
Non-cash legal expense
34,881
–
Non-cash interest expense
11,563
17,504
Non-cash operating lease expense
124
–
Changes in operating assets and liabilities:
Accounts receivable, net
( 791,239 )
361,916
Inventories
( 694,012 )
( 91,884 )
Prepaid expenses
( 86,026 )
( 49,683 )
Accounts payable
1,511,787
( 1,034,951 )
Contract liabilities
649,579
( 2,340 )
Accrued compensation and other
( 76,658 )
( 104,363 )
Net cash used in operating activities
( 3,547,400 )
( 2,683,012 )
Cash Flows from Investing Activities:
Reclassification/additional patent costs
( 6,264 )
( 21,448 )
Purchases of property and equipment
( 227,209 )
( 272,435 )
Net cash used in investing activities
( 233,473 )
( 293,883 )
Cash Flows from Financing Activities:
Payment of capital lease obligations
( 41,114 )
( 43,209 )
Principal payments of long-term debt
( 280,440 )
( 513,259 )
Payment of debt issuance costs
( 40,000 )
–
(Repayments)/Borrowings on line of credit
( 1,000,000 )
1,000,000
Gross proceeds from registered direct offerings of common stock
6,270,136
–
Stock issued for services
151,698
–
Gross proceeds from exercise of stock options
89,050
12,789
Net cash provided by financing activities
5,149,330
456,321
Net increase (decrease) in cash and cash equivalents
1,368,457
( 2,520,574 )
Cash and cash equivalents, beginning of year
405,278
2,925,852
Cash and cash equivalents, end of year
$ 1,773,735
$ 405,278
Supplemental disclosure of cash flow information:
Cash paid during the year for income taxes
$ 1,936
$ 1,936
Cash paid during the year for interest
$ 216,456
$ 207,604
Operating right-of-use assets obtained in exchange for operating lease liabilities
$ 133,650
$ –
The accompanying notes are an integral part
of these financial statements.
F- 6
PRECISION OPTICS CORPORATION, INC.
Notes to Financial Statements
(1)
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
(a)
Nature of Business
Precision Optics Corporation, Inc. (the “Company”)
designs, develops, manufactures and sells specialized optical and illumination systems and related components. The Company conducts business
in one industry segment only and its customers are primarily domestic. The Company performs advanced optical and illumination system design,
development, assembly and manufacturing services, and sources for resale specialized optical components for products that fall into two
principal areas: (i) medical products for use by hospitals and physicians; and (ii) products used by defense contractors, aerospace and
industrial customers.
(b)
Revenues
The Company determines revenue recognition for
arrangements that we determine are within the scope of Accounting Standards Codification Topic 606, Revenue from Contracts with Customers ,
(“ASC 606”), by performing the following five steps: (i) identify the contract with a customer; (ii) identify the performance
obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations
in the contract; and (v) recognize revenue when, or as, we satisfy the performance obligations. At contract inception, once the contract
is determined to be within the scope of ASC 606, we assess the goods or services promised within the contract and determine those that
are performance obligations and assess whether each promised good or service is distinct based on the contract.
The Company disaggregates revenues by product
and service types as it believes best depicts how the nature, amount, timing and uncertainty of revenues and cash flows are affected by
economic factors. Revenues are comprised of the following for year ended June 30, 2025, and 2024:
Schedule of disaggregation of revenues
Year Ended June 30,
2025
2024
Engineering Design Services
$ 4,938,158
$ 8,519,130
Systems Manufacturing
8,290,225
3,731,754
Micro Optics Lab
2,135,562
2,720,925
Ross Optical Industries
3,727,324
4,132,541
Total Revenues
$ 19,091,269
$ 19,104,350
Selling costs to obtain and fulfill contracts
are expensed as incurred due to the short-term nature of a majority of contracts. The Company extends terms of payment to its customers
based on commercially reasonable terms for the markets of its customers, while also considering their credit quality. Shipping and handling
costs charged to customers are included in revenue.
Revenue recognition policies for each of the three
product and service types appear below.
Engineering Design Services
The Company enters into contractual agreements
with our customers, including design services agreements, statements of work and receive purchase orders for development projects. These
agreements provide costs on an estimated basis for the services we have agreed to provide. Engineering Design Services are rendered on
a time and materials basis. The Company recognizes revenue as customers are invoiced for the actual engineering services provided in the
period. Revenue is also recognized on materials purchased for development projects at the time of receipt. Engineering Design Services
are provided on a best-efforts basis; no warranty is provided as there is no guarantee that the work will result in the attainment of
the customer’s project objectives. The Company may obtain customer deposits in advance of rendering engineering design services.
Customer deposits are treated as contractual liabilities until the terms of customer agreements are satisfied and are not a component
of revenue.
F- 7
Systems Manufacturing, Micro Optics Laboratory,
Ross Optical Industries
The Company provides fixed price quotations to
our customers and requires purchase orders for items manufactured and distributed through the Systems Manufacturing, Micro Optics Laboratory
and Ross Optical Industries business units. Revenue is recognized at the time title passes to our customer based on our review of the
customer contract, generally at the time of shipment from our facilities. Occasionally the Company may enter into “bill and hold”
contractual arrangements where title is held by our customers while goods are stored at our facilities for their convenience.
Contract Assets and Liabilities
The nature of the Company’s products and
services does not generally give rise to contract assets as it typically does not incur costs to fulfill a contract before a product or
service is provided to a customer. The Company’s costs to obtain contracts are typically in the form of sales commissions paid to
employees. The Company has elected to expense sales commissions associated with obtaining a contract as incurred as the amortization period
is generally less than one year. These costs have been recorded in selling, general and administrative expenses. As of June 30, 2025 and
2024, there were no contract assets recorded in the Company’s Balance Sheets.
The Company’s contract liabilities arise
as a result of unearned revenue received from customers at inception of contracts or where the timing of billing for services precedes
satisfaction of performance obligations. The Company generally satisfies performance obligations within one year from the contract inception
date.
Contract liabilities, which were recorded as customer
advances in the Company’s Balance Sheets, and unearned revenue are comprised of the following:
Schedule of contract liabilities
Year Ended June 30,
2025
2024
Contract liabilities, beginning of period
$ 1,172,350
$ 1,174,690
Unearned revenue received from customers
1,364,332
1,946,946
Revenue recognized
( 714,753 )
( 1,949,286 )
Contract liabilities, end of period
$ 1,821,929
$ 1,172,350
(c)
Cash and Cash Equivalents
The Company includes in cash equivalents all highly
liquid investments with original maturities of three months or less at the time of acquisition. Cash and cash equivalents of $ 1,773,735
and $ 405,278 on June 30, 2025 and 2024, respectively, consist primarily of cash at banks and money market funds. The Company maintains
its cash and cash equivalents in bank deposit accounts that, at times, may exceed federally insured limits. The Company has not experienced
any losses in such accounts. The Company believes it is not exposed to any significant credit risk on its cash and cash equivalents.
(d)
Inventories
Inventories are stated at the lower of cost (first-in,
first-out) and net realizable value and include material, labor and manufacturing overhead. The components of inventories on June 30,
2025 and 2024 are as follows:
Schedule of inventory
2025
2024
Raw material
$ 1,799,624
$ 1,570,135
Work-in-progress
598,720
157,406
Finished goods
1,163,768
1,140,559
Total Inventories (Net)
$ 3,562,112
$ 2,868,100
F- 8
The Company provides for estimated
obsolescence on unmarketable inventory based upon assumptions about future demand and market conditions. If actual demand and market
conditions are less favorable than those projected by management, additional inventory write-downs may be required. Inventory, once
written down, is not subsequently written back up, as these adjustments are considered permanent adjustments to the carrying value
of the inventory. The reserve for excess and obsolete inventory for the years ended June 30, 2025 and 2024, were $ 272,894
and $ 266,843 ,
respectively.
(e)
Fixed Assets
Fixed assets are recorded at cost. Maintenance
and repair items are expensed as incurred. The Company provides for depreciation and amortization by charges to operations, using the
straight-line and declining-balance methods, which allocate the cost of fixed assets over the following estimated useful lives:
Schedule of estimated useful lives
Asset Classification
Estimated Useful Life
Machinery and equipment
2-7 years
Leasehold improvements
Shorter of lease term or estimated useful life
Furniture and fixtures
5 years
Depreciation expense was $ 186,990 and $ 212,382
for the years ended June 30, 2025 and 2024, respectively.
(f)
Significant Customers and Concentration of Credit Risk
Financial instruments that subject the Company
to credit risk consist primarily of cash equivalents and trade accounts receivable. The Company places its investments with highly rated
financial institutions. The Company has not experienced any losses on these investments to date. At June 30, 2025, and 2024, two
individual customers accounted for more than 10 % of the Company’s total accounts receivable.
The allowance for credit losses was $ 80,192 at
June 30, 2025, and $ 118,872 at June 30, 2024.
Schedule of allowance for credit losses
Year Ended June 30,
2025
2024
Allowance for credit losses, beginning of period
$ 118,872
$ 606,715
Change in the provision for expected credit losses
( 44,858 )
( 23,541 )
Writeoffs charged against the allowance
6,178
( 464,302 )
Allowance for credit losses, end of period
$ 80,192
$ 118,872
The Company generally does not require collateral
or other security as a condition of sale, rather it relies on credit approval, balance limitation and monitoring procedures to control
credit risk in trade account financial instruments. Management believes the allowance for credit losses, which is established based upon
review of specific account balances and historical experience, is adequate at June 30, 2025.
(g)
Loss per Share
Basic income (loss) per share is computed by dividing
net income or net loss by the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per
share is computed by dividing net income or net loss by the weighted average number of shares of common stock outstanding during the period,
plus the number of potentially dilutive securities outstanding during the period such as stock options and warrants. For the years ended
June 30, 2025 and 2024, the effect of such securities was antidilutive and not included in the diluted calculation because of the net
loss generated in those periods.
F- 9
The following is the calculation of loss per share
for the years ended June 30, 2025 and 2024:
Schedule of loss per share
Year Ended June 30,
2025
2024
Net Loss– Basic and Diluted
$ ( 5,780,246 )
$ ( 2,951,377 )
Basic and diluted weighted average shares outstanding
6,790,466
6,068,329
Loss per share
Basic and fully diluted
$ ( 0.85 )
$ ( 0.49 )
The number of shares issuable upon the exercise
of outstanding stock options and warrants that were excluded from the computation as their effect was antidilutive was approximately 1,623,576
and 1,357,735 for the years ended June 30, 2025 and 2024, respectively.
(h)
Stock-Based Compensation
The measurement and recognition of compensation
costs for all stock-based awards made to employees and the Board of Directors are based upon fair value over the requisite service period
for awards expected to vest. The Company estimates the fair value of share-based awards on the date of grant using the Black-Scholes option-pricing
model. Stock-based compensation costs recognized for the years ended June 30, 2025, and 2024 amounted to $ 1,612,106 and $ 959,784 , respectively.
(i)
Goodwill and Patents
Long-lived assets such as goodwill and patents
are capitalized when acquired and reviewed for impairment on an annual basis or whenever events or changes in circumstances indicate that
the book value of the asset may not be recoverable. Impairment of the carrying value of long-lived assets such as goodwill and patents
would be indicated if the best estimate of future undiscounted cash flows expected to be generated by the asset grouping is less than
its carrying value. If an impairment is indicated, any loss is measured as the difference between estimated fair value and carrying value
and is recognized in operating income or loss. Assets to be disposed of are reported at the lower of the carrying amount or fair value
less costs to sell. No such impairments of goodwill or patents have been estimated by management during the years ended June 30, 2025
or 2024. Amortization expense for the year ended June 30, 2025 and 2024 was $ 25,448 and $ 0 , respectively.
(j)
Fair Value of Financial Instruments
Financial instruments consist principally of cash
and cash equivalents, accounts receivable and accounts payable. The estimated fair value of these financial instruments approximates their
carrying value due to their short-term nature.
(k)
Research and Development
Research and development expenses are charged
to operations as incurred. The Company groups development and prototype costs and related reimbursements in research and development.
There were no reimbursements for research and development recorded in research and development for the years ended June 30, 2025, and
2024.
(l)
Comprehensive Income
Comprehensive income or loss is defined as the
change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources.
The Company’s comprehensive loss or income for the years ended June 30, 2025 and 2024 was equal to its net loss for the same periods.
F- 10
(m)
Income Taxes
Income taxes are accounted for under the asset
and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between
the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax
credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in
the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities
of a change in tax rates is recognized in income in the period that includes the enactment date. In assessing the likelihood of utilization
of existing deferred tax assets, management has considered historical results of operations and the current operating environment.
(n)
Segment Reporting
Operating segments are identified as components
of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker,
or decision-making group, in making decisions about how to allocate resources and assess performance. The Company’s chief decision-maker
is its Chief Executive Officer. To date, the Company has viewed its operations and manages its business as principally one segment.
(o)
Use of Estimates
The preparation of financial statements in conformity
with accounting standards generally accepted in the United States requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements
and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
(p)
Recent Accounting Pronouncements
In December 2023, the FASB issued ASU No. 2023-09,
Improvements to Income Tax Disclosures (Topic 740). The guidance requires disclosure of disaggregated income taxes paid, prescribes standardized
categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. The standard
will be effective for us beginning with our annual reporting for fiscal year 2026, with early adoption permitted. We are currently evaluating
the impact of this standard on our income tax disclosures.
In November 2024, the FASB issued ASU 2024-03,
Income Statement - Reporting Comprehensive Income (Topic 220): Expense Disaggregation Disclosures. Additionally, in January 2025, the
FASB issued ASU 2025-01 to clarify the effective date of ASU 2024- 03. This ASU provides guidance to expand disclosures related to the
disaggregation of income statement expenses. This ASU also requires, in the notes to the financial statements, disclosure of specified
information about certain costs and expenses which includes purchases of inventory, employee compensation, depreciation, and intangible
asset amortization included in each relevant expense caption. ASU 2025-01 is effective for fiscal years beginning after December 15, 2026,
and interim periods within annual reporting periods beginning after December 15, 2027, on a retrospective or prospective basis, with early
adoption permitted. This ASU will be effective for the Company’s Form 10-K for fiscal 2028 and Form 10-Q filed thereafter. The Company
is currently evaluating the impact this ASU may have on our financial statement disclosures.
(2)
COMMITMENTS
(a)
Bank Financing Activities
Bank Term Loan and Line of Credit
On October 4, 2021, the Company entered into a
Loan Agreement with Main Street Bank of Marlborough, Massachusetts (the “Lender”), which provided for a $2,600,000 Term Loan
and a $250,000 Revolving Line of Credit Loan Facility (the “Revolver”), which was increased to $500,000 effective May 17,
2022, and $1,250,000 effective June 2, 2023. Borrowings under the Revolver are limited by the borrowing base comprised of a percentage
of accounts receivable and inventory and secured by all assets of the Company. Borrowings under the Revolver will bear interest payable
monthly at the prime lending rate plus 1.5% per annum and shall not be less than 4.75% per annum. Borrowings under the Revolver are due
upon demand. There were no borrowings under the Revolver at June 30, 2025.
F- 11
The Company’s Loan Agreement with the Lender
contains a minimum annual debt service coverage ratio covenant of 1.2x. The Company did not meet this annual debt service coverage ratio
for the fiscal year ended June 30, 2024. The Company’s Lender has agreed to waive compliance with such debt service ratio covenant
for the period ending June 30, 2024. In addition to such waiver, the Lender and the Company have entered into an amendment dated September
30, 2024 to that certain Term Loan dated October 4, 2021, as amended and that certain Promissory Note dated June 2, 2023 (collectively,
the “Notes”) which amendments provide for a six-month period of interest only payments from October 15, 2024 through March
15, 2025 for the Notes. The Company commenced payments of principal and interest under the Notes beginning with the payments due on April
15, 2025, with a new amortization schedule for the remaining term for such Notes through their maturity date. On February 14, 2025, the
lender agreed to waive compliance with the annual debt service coverage ratio covenant for the fiscal year ending June 30, 2025, subject
to a $30,000 waiver fee and the completion of an equity raise of at least $4,500,000 by February 24, 2025, which the Company satisfied
on February 21, 2025. Any future advances are contingent on the Company achieving a minimum Debt Service Coverage ratio of 1.20x based
on quarterly testing. There were no other changes to or modifications to the Loan Agreement or the Notes.
Long-Term Debt
Long-term debt consists of the following at June
30, 2025 and 2024:
Schedule of long-term debt
2025
2024
Term Loan Note payable to Main Street Bank with monthly principal payments of $ 35,271 , excluding six months in Fiscal 2025, plus interest at a fixed rate of 7.0 % per annum. Secured by all assets of the Company, and subject to certain periodic reporting to the bank and other conditions including an annual minimum EBITDA plus stock-based compensation to debt service coverage ratio of 1.20:1 commencing with the fiscal year ending June 30, 2023. The Term Loan Note matures on October 15, 2028 .
$ 1,410,853
$
1,609,524
Permanent Working Capital Loan payable to Main Street Bank with monthly principal payments of $ 14,423 , excluding six months in Fiscal 2025, plus interest at a fixed rate of 8.625 % per annum. Secured by all assets of the Company, and subject to certain periodic reporting to the bank and other conditions including an annual minimum EBITDA plus stock-based compensation to debt service coverage ratio of 1.20:1 commencing with the fiscal year ending June 30, 2023. The Permanent Working Capital Loan matures on June 15, 2028 .
519,231
600,000
Less current maturities
( 577,898 )
( 276,928
)
Less debt issuance costs, net of accumulated amortization of $ 29,756
and $14,360, respectively.
( 62,981 )
( 33,544
)
Long-term debt, net of current portion of debt issuance costs
$ 1,289,205
$
1,899,052
At June 30, 2025 principal payments due
on long-term debt are as follows:
Schedule of principal payments due on term loan note payable
Fiscal Year Ending June 30:
2026
$ 596,333
2027
596,333
2028
596,333
2029
141,085
Total long-term debt
$ 1,930,084
F- 12
(b)
Lease Obligation
In March 2021 the Company entered into a five-year
capital lease in the amount of $ 161,977 and in January 2020, the Company entered into a five-year capital lease for $ 47,750 , both for
manufacturing equipment. The net book value of fixed assets under capital lease obligations as of June 30, 2025 is $ 27,368 .
On July 1, 2019 the Company entered into a three-year
operating lease for its facility in El Paso, Texas, and in February 2022 the Company entered into an extension of the lease for an additional
three years through June 2025. In May 2025, this lease was extended for an additional three years through May 2028. Remaining minimum
lease payments at June 30, 2025 total $ 148,029 . Total lease costs including base rent and common area expenses was $ 67,552 and $ 64,621
during the fiscal years ended June 30, 2025 and 2024, respectively. On October 4, 2021 the Company assumed the remaining term of the Windham
Maine lease as part of the Lighthouse acquisition. The lease expired on July 31, 2025. Remaining minimum lease payments at June 30, 2025
total $ 11,477 . Total lease costs including base rent and common area expenses was $ 137,728 and $ 137,728 during the fiscal year ended June
30, 2025 and 2024, respectively. The amount of variable lease payments is immaterial. Included in the accompanying balance sheet at June
30, 2025 is a right-of-use asset of $ 141,825 and current and long-term right-of-use operating lease liabilities of $ 50,995 and $ 90,954 ,
respectively.
On May 15, 2025 the Company entered into an seven-year
lease in South Portland, Maine with two five-year extension options. On June 2, 2025 the Company entered into a seven-year operating lease
in Littleton, Massachusetts with two five-year extension options.
As of June 30, 2025, the Company had entered into
additional operating leases with total fixed payment obligations of $ 3.8 million that have not yet commenced. The leases are expected
to commence in fiscal year 2026 and have initial lease terms of approximately 8 years.
At June 30, 2025 future minimum lease payments
under the capital lease and operating lease obligations are as follows:
Schedule of future minimum lease payments under capital lease and operating lease obligations
Fiscal Year Ending June 30:
Capital Leases
Operating Lease
2026
$ 28,004
$ 60,819
2027
–
50,823
2028
–
47,864
Total Minimum Payments
28,004
159,506
Less: amount representing interest
637
17,557
Present value of minimum lease payments
27,368
141,949
Less: current portion
27,368
50,995
Future minimum long-term lease liability
$ –
$ 90,954
The Company’s four facilities in Gardner,
Massachusetts, which are used for offices, production and storage spaces, are leased primarily on a tenant-at-will basis. Rent expense
on these operating leases was $ 206,309 and $ 200,678 for the fiscal years ended June 30, 2025 and 2024, respectively.
(3)
STOCKHOLDERS’ EQUITY
(a)
Stock-Based Compensation Expense
The following table summarizes stock-based compensation
expense for the years ended June 30:
Schedule of stock-based compensation
expense
2025
2024
Cost of Goods Sold
$ 154,559
$ 93,713
Selling, General and Administrative Expenses
1,457,547
866,071
Stock Based Compensation Expense
$ 1,612,106
$ 959,784
F- 13
As of June 30, 2025, the unrecognized compensation
costs related to options vesting in the future was $ 1,409,980 . No compensation has been capitalized because such amounts would have been
immaterial. There was no net income tax benefit recognized related to such compensation for the years ended June 30, 2025, or 2024, as
the Company is currently in a loss position. There were 520,000 stock options granted during the year ended June 30, 2025, and 285,527
stock options granted during the year ended June 30, 2024.
The Company uses the Black-Scholes option-pricing
model as the most appropriate method for determining the estimated fair value for the stock awards. The Black-Scholes method of valuation
requires several assumptions: (1) the expected term of the stock award; (2) the expected future stock volatility over the expected term;
and (3) risk-free interest rate. The expected term represents the expected period of time the Company believes the options will be outstanding
based on historical information. Estimates of expected future stock price volatility are based on the historic volatility of the Company’s
common stock, and the risk-free interest rate is based on the U.S. Zero-Bond rate. The Company utilizes a forfeiture rate based on an
analysis of the Company’s actual experience. The fair value of options at date of grant was estimated with the following assumptions
for options granted in fiscal year 2025:
Schedule of fair value of option assumptions
Year Ended
June 30, 2025
June 30, 2024
Assumptions:
Option life
6.25 years
6.25 years
Risk-free interest rate
4.02 - 4.52 %
4.35 - 4.47 %
Weighted average stock volatility
98.12 %
99.4 %
Dividend yield
0.0 %
0.0 %
Weighted average fair value of grants
$ 3.84
$ 4.69
(b) Stock Option Plans
The type of share-based payments currently utilized
by the Company is stock options.
The Company has four stock option plans outstanding
as of June 30, 2025, namely the Precision Optics Corporation, Inc. 2022 Equity Incentive Plan (the “2022 Plan”), the Precision
Optics Corporation, Inc. 2021 Equity Incentive Plan (the “2021 Plan”), the Precision Optics Corporation, Inc. 2011 Equity
Incentive Plan (the “2011 Plan”) and the Precision Optics Corporation, Inc. 2006 Equity Incentive Plan (the “2006 Plan”).
Vesting periods under each of the Plans are at the discretion of the Board of Directors and typically average three years and in some
instances are subject to future performance criteria. Options under these Plans are granted at fair market value on the date of grant
and typically have an initial term of ten years from the date of grant, subject to certain cancellation provisions such as upon employment
termination. The Company has filed Registration Statements on Form S-8 with the Securities and Exchange Commission to register all shares
of common stock issuable under the 2022, 2021, 2011, and 2006 Plans.
On April 8, 2022, our Shareholders approved the
2022 Plan which provides eligible participants (certain employees, directors, consultants, etc.) the opportunity to receive a broad variety
of equity based and cash awards. A maximum of 933,333 shares of the Company’s common stock may be issued pursuant to stock options
or other awards under the 2022 Plan. At June 30, 2025, options for a total of 876,091 shares of common stock were outstanding and 57,242
shares of common stock were available for future grants under the 2022 Plan. The 2022 Plan permits the Board of Directors to authorize
and increase up to 5% of the then outstanding shares on an annual basis.
On May 10, 2021, our Board of Directors approved
the 2021 Plan which likewise authorizes a broad variety of equity based and cash awards. A maximum of 333,333 shares of the Company’s
common stock may be issued under the 2021 Plan. At June 30, 2025, options for a total of 264,495 shares of common stock were outstanding
under the 2021 Plan. No further shares may be issued from this plan.
The 2011 Plan and 2006 Plan likewise provided
for a broad variety of equity based and cash awards, but terminated in 2021 and 2016, respectively. At June 30, 2025, options for 482,990
shares of common stock were outstanding under the 2011 Plan. At June 30, 2025, options for a total of zero shares of common stock were
outstanding under the 2006 Plan.
F- 14
The following tables summarize stock option activity
for the years ended June 30, 2025 and 2024:
Schedule of stock option activity
Options Outstanding
Number of
Shares
Weighted
Average
Exercise Price
Weighted
Average
Contractual
Life
Outstanding at June 30, 2023
1,127,140
$ 4.54
6.88 years
Grants
285,257
5.76
Exercised
( 10,332 )
2.70
Cancellations
( 44,330 )
4.18
Outstanding at June 30, 2024
1,357,735
$ 4.72
6.60 years
Grants
520,000
4.78
Exercised
( 129,329 )
2.79
Cancellations
( 84,664 )
5.34
Outstanding at June 30, 2025
1,623,576
$ 4.85
7.15 years
The aggregate intrinsic value of the Company’s
“in-the-money” outstanding and exercisable options as of June 30, 2025, was $ 833,438 and $ 787,363 , respectively.
(c)
Sale of Stock in August 2024
On August 14, 2024, the Company entered into agreements
with certain institutional and accredited investors, in addition to certain directors and officers of the Company, for the sale and purchase
of 265,868 shares of the Company’s common stock pursuant to a registered direct offering at a purchase price of $ 5.25 per share
for the institutional and unaffiliated accredited investors and $ 5.79 per share for the directors and officers, resulting in gross proceeds
of approximately $1.4 million before deducting placement agent commissions and other estimated offering expenses. Net proceeds were approximately
$ 1.2 million.
(d)
Sale of Stock in February 2025
On February 19, 2025, the Company entered into
agreements with certain institutional and accredited investors for the sale and purchase of 1,272,500 unregistered shares of its common
stock, $ 0.01 par value at a purchase price of $ 4.00 per share, resulting in gross proceeds of approximately $ 5.1 million before deducting
placement agent commissions and other estimated offering expenses. The Company used the net proceeds from this placement for general
working capital needs and paydown of the Company’s line of credit.
(4)
INCOME TAXES
The Company has identified its federal tax return
and its state tax return in Massachusetts as “major” tax jurisdictions. The periods subject to examination for its federal
and state income tax returns are the years ended in 2018 and thereafter. The Company believes its income tax filing positions and deductions
will be sustained on audit and it does not anticipate any adjustments that would result in a material change to its financial position.
Therefore, no liabilities for uncertain income tax positions have been recorded.
The provision for income taxes in the accompanying
consolidated statements of operations consists of the state income tax liability of $ 1,936 for the years ended June 30, 2025, and 2024.
F- 15
A reconciliation of the federal statutory rate
to the Company’s effective tax rate for the fiscal years ended June 30, 2025 and 2024 is as follows:
Schedule of effective income tax rate reconciliation
2025
2024
Income tax expense (benefit) at federal statutory rate
( 21.0 )%
( 21.0 )%
Increase (decrease) in tax resulting from:
State taxes, net of federal benefit
( 6.3 )%
( 6.3 )%
Change in valuation allowance
20.8 %
16.3 %
Stock based compensation
6.9 %
10.5 %
Nondeductible items
( 0.4 )%
0.4 %
Effective tax rate
0.0
%
0.0 %
The components of deferred tax assets and liabilities
at June 30, 2025 and 2024 are approximately as follows:
Schedule of deferred tax assets and liabilities
2025
2024
Deferred tax assets:
Net operating loss carry forwards
$ 4,854,000
$ 3,999,000
Tax credit carry forwards
338,000
353,000
Reserves and accruals not yet deducted for tax purposes
778,000
254,000
Total deferred tax assets
5,970,000
4,606,000
Valuation allowance
( 5,970,000 )
( 4,606,000 )
Net deferred tax asset
$ –
$ –
The Company has provided a valuation allowance
to reduce the net deferred tax asset to an amount the Company believes is “more likely than not” to be realized.
At June 30, 2025, the Company had federal and
state net operating loss carry forwards of approximately $ 23,116,000 and $ 11,674,000 , respectively, which will, if not used, expire at
various dates beginning in fiscal year 2026.
(6)
PROFIT SHARING PLAN
The Company has a defined contribution 401(k)
profit sharing plan. Employer profit sharing and matching contributions to the plan are discretionary. No employer profit sharing or matching
contributions were made to the plan in fiscal years 2025 and 2024.
F- 16
ITEM 9. CHANGES IN AND DISAGREEMENTS
WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.
None.
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.